C - Chemistry – Metallurgy – 07 – K
Patent
C - Chemistry, Metallurgy
07
K
C07K 16/18 (2006.01) A61K 39/00 (2006.01) A61K 39/395 (2006.01) A61P 37/06 (2006.01) C07H 21/04 (2006.01) C12N 5/12 (2006.01) C12N 15/12 (2006.01)
Patent
CA 2424379
The invention relates to C5 inhibitors, whic inhibit type II edothelial cell activation, wehrein the inhibition is manifested by the suppresion of E- selectin. These inhibitors are useful in treatment of delayed xenograft rejection or acute vascular rejection. The inhibitors include antibody molecules, as well as homologues, analogues and modified or derived forms thereof, including immnoglobulin fragments like Fab, F(ab')2 and Fv, small molecules, including peptides, oligonucleotides, peptidominetics and organic compounds. Examples of monoclonal antibodies, which bind to and inhibit C5, were generated and are designated MAb 137-76 and MAb 137-30.
Cette invention concerne des inhibiteurs C5, qui inhibent l'activation de cellules endothéliales de type II, l'inhibition se manifestant par la suppression de la sélectine-E. Ces inhibiteurs conviennent bien pour le traitement de rejet différé de xénogreffe ou de rejet vasculaire aigu. Ils comprennent des molécules d'anticorps ainsi que des homologues, des analogues ou des formes dérivées de ces molécules, dont des fragments d'hémoglobine comme Fab, F(ab')¿2? et Fv, des petites molécules dont des peptides, des oligonucléotides, des peptidomimétiques et des composés organiques. Des exemples d'anticorps monoclonaux, qui se lient à C5 et l'inhibent, ont été produits sous l'appellation de MAb 137-76 et MAb 137-30.
Fung Michael S.c.
Sun Bill N. C.
Sun Cecily R.y.
Genentech Inc.
Sim & Mcburney
Tanox Inc.
LandOfFree
Inhibition of complement c5 activation for the treatment and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhibition of complement c5 activation for the treatment and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibition of complement c5 activation for the treatment and... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1941379